ABSTRACT
This study gives a comprehensive picture of various trends of worldwide scientific research on the impact of COVID-19 on social media marketing from 2019 to early 2022. Relevant articles were retrieved from the Scopus database using specific keywords, and a bibliometric analysis was performed in Biblioshiny, an R-based software package. An examination of a total of 603 papers on the themes 'COVID-19' and 'social media marketing' indicated reasonably good collaboration among authors and a whooping scientific production worldwide in the last two years. Bina Nusantara University was the highest contributor to the chosen theme used in the study. Indonesia topped the list in single country publications. The UK had the highest multiple country publication. The UK, China, Spain, and India were the most cited countries. The output of the study may help the researchers and marketers understand the trending areas in social media marketing during COVID-19. © 2023 IGI Global. All rights reserved.
ABSTRACT
Wellness tourism is emerging as one of the most preferred tourism segments for both travel enthusiasts and ordinary vacation seekers due to the COVID-19 pandemic and the resultant stress and anxiety. It is a niche tourism segment with enormous ability to emerge as the most in demand for coming years. This study carries out a bibliometric analysis to identify the prominent journals, their characteristics and total citations, trending keywords, emerging topics etc, in wellness tourism. With 159 articles extracted from the Web of Science database, it was observed that the word ‘health' was often used, and that ‘medical tourism' was the most popular topic. China takes the lead among world nations for having conducted most research in this field. The findings of the study could be beneficial to the research community, academia, the tourism industry and policymakers. The publication acknowledges its limitations but gives the implications for further research. © by the author, licensee University of Lodz – Lodz University Press, Lodz, Poland.
ABSTRACT
Background and Objectives: Globally, suicide is a pertinent public health crisis that affects almost all nations cross-culturally. Suicide is one of the leading causes of death in many countries, even before the COVID-19 pandemic hit worldwide. India, a nation developing rapidly, is also not free from the leashes of suicide deaths. COVID-19 augmented the rate of suicide due to multifaceted determinants. Adequate empirical evidence about data on suicide is also scarce. Materials and Methods: This review synthesizes determinants, available demographic correlates, and reported rates of suicide published in the Indian context. The authors conducted a thorough literature search to find published English free full-text scientific articles related to suicide during the COVID-19 pandemic in the Indian context. Databases relied on for literature were PubMed, Google scholar, and PLOS one databases using comprehensive search strategies to avail the maximum number of studies. Results: Ten out of 76 studies available in the initial search were analyzed thoroughly for ruling out determinants, rates, and sociodemographic correlates of suicide. Fear of COVID-19 infection, financial crisis, mental breakdown, and job loss are cardinal reasons attributed for suicide, and male suicides are more prevalent in this arena. Interpretation and Conclusions: Findings portray factors such as fear of COVID-19 diagnosis, apprehension to become infected, financial crisis, loss of job, and isolation are some of the significant determinants quoted out. The study points out the need for multifaceted policies in preventing this public health crisis.
ABSTRACT
Background: Pausing methotrexate (MTX) for two to four weeks, improved immunogenicity of infuenza vaccination in patients with rheumatoid arthritis (RA), albeit a risk of disease fare (1). This guided the framing of guidelines on MTX withdrawal for COVID-19 vaccination (2). However, evidence for MTX withdrawal for COVID-19 vaccination is limited to observational studies only. Objectives: To compare the efficacy and safety of holding MTX after each (MIVAC 1) and only after the second dose (MIVAC II) of the ChAdOx1 vaccine versus continuation of MTX in two randomized controlled trials (RCTs). Methods: Two single centre, investigator-blinded, RCTs were conducted in patients with RA or Psoriatic arthritis (PsA) on stable doses of MTX without prior COVID-19 (CTRI reg. no. MIVAC I: CTRI/2021/07/03463 & MIVAC II: CTRI/2021/07/035307). In MIVAC I, unvaccinated patients were randomised (1:1) to hold or continue MTX for two weeks after each dose of the vaccine. MIVAC II included patients who had continued MTX during the frst dose of ChA-dOx1 and were randomised (1:1) to hold or continue MTX for 2 weeks after the second vaccine dose. The primary outcome for both the trials was the anti-Receptor Binding Domain (RBD) antibody titres measured four weeks after the second vaccine dose (per protocol analysis). Secondary outcome was the fare rate, defned as an increase in disease activity scores (DAS28/cDAPSA) or physician intent to hike DMARDs. Results: 250 patients were randomized for MIVAC 1 and 178 for MIVAC II and after due exclusions, 158 and 157 were eligible for analysis respectively (Figure 1). In MIVAC I, median anti-RBD titres were signifcantly high in the MTX hold group [2484 (1050-4388) versus 1147(433-2360), p=0.001] but the fare rate was higher in the hold group [20 (25%) versus 6(8%) p=0.005] compared to continue group. In MIVAC II median anti-RBD titres were signifcantly high for the MTX hold group [2553 (1792-4823) versus 990 (356-2252), p=0.001] when compared to continue group but there was no difference in the fare rate between the groups [9(11.8%) and 4(7.9%), p=0.15] (Table 1). Since both were parallel studies in similar population, MTX hold arms across both the trials were compared for anti-RBD titres and fare. There was no difference in the anti-RBD titres [p=0.2] between the groups. In MIVAC I, 29(36.25%) patients had reported fare (19 in either frst or second dose, 10 for both doses) when compared to MIVAC II where only 9(11.84%) patients had reported fare after the second dose (P <0.001). Conclusion: Holding MTX after both the doses or only after the second dose of ChAdOx1 yields higher anti-RBD antibody titres as compared to continuing MTX. Comparing across the trials, holding MTX only after the second dose appears to be non-inferior to holding MTX after both doses of the vaccine with a lesser risk of fare.